

Consent letter

26 January 2026

The Board of Directors

Shandong Weigao Group Medical Polymer Company Limited

Dear Sirs,

Shandong Weigao Group Medical Polymer Company Limited (the “Company”, together with its subsidiaries, the “Group”)

Major Transactions of the Company

We refer to the circular dated 26 January 2026(the “Circular”) in connection with the proposed major transactions of the Company, a copy of which is attached and initialed by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants report on the historical financial information of the Shandong Weigao Blood Purification Products Co., Ltd., the target company in major transactions, for the year ended 31 December 2022, 2023, 2024 and nine months ended 30 September 2025 in the Circular, and the references to our name in the form and context in which they are included.

This letter is solely being issued in connection with the filing of the Circular regarding the major transactions on The Stock Exchange of Hong Kong Limited and not for any other purpose.

Yours faithfully,

Ernst & Young Hua Ming LLP

Certified Public Accountants

Beijing, the People's Republic of China